(Audio: Chinese-English with bilingual translation) COVID-19 case discussion between Chinese and Malaysian doctors was held on 26th of March 2020.
- Q1: Role of Favipravir in treatment of COVID-19 cases 00:26:34
- Q2: Comment of Malaysia COVID-19 treatment protocol 00:35:38
- Q3: Cytokine Release Syndrome in COVID-19 00:52:03
- Q4: Role of steroids in treatment of COVID-19 cases 01:02:36
- Q5: Role of Interleukin-6 (IL-6) inhibitor in treatment of COVID-19 cases 01:09:29
- Q6: Experience in usage of convalescent serum 01:14:17
- Q7: Management of healthcare workers who exposed to positive COVID-19 patients without proper personal protection equipment (PPE). 01:22:04
- Q8: Re-infection of COVID-19 01:34:09
- Q9: Infectivity of patients who had recovered from the illness, but PCR test remains positive beyond 14 days 01:46:30
The summary of this video is available on google slide via https://cutt.ly/atQRllw
Opening address by
- His Excellency Bai Tian, Ambassador Extraordinary and Plenipotentiary of the People's Republic of China to Malaysia,
- Mr Bei Zhaojian, Deputy Director-General of the Shanghai Municipal Foreign Affairs Office and
- Dr. Hishamshah Bin Mohd Ibrahim, Deputy Director General Of Health (Research & Technical Support), Ministry Of Health Malaysia representing YBhg.Dato’ Seri Dr. Chen Chaw Min, Chief Secretary, Ministry of Health Malaysia.
Experts from China are:
- Dr. Qiu Zhongmin, Director of Department of Pulmonary and Critical Care Medicine, Tongji University School of Medicine, Shanghai
- Profesor Dr. Shen Yinzhong, Director of Department of Medical Administration, Shanghai Public Health Clinical Center and Chief Physician, Department of Infection and Immunity Shanghai
Also attended this video conference were the Infectious Disease Physicians and Specialists from 17 MOH Malaysia hospitals from all the 14 states and University Malaya (UM).
